"Vasoconstrictor Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Drugs used to cause constriction of the blood vessels.
| Descriptor ID |
D014662
|
| MeSH Number(s) |
D27.505.954.411.793
|
| Concept/Terms |
Vasoconstrictor Agents- Vasoconstrictor Agents
- Agents, Vasoconstrictor
- Vasoconstrictor Drugs
- Drugs, Vasoconstrictor
- Vasoconstrictors
- Vasoactive Agonists
- Agonists, Vasoactive
- Vasopressor Agents
- Agents, Vasopressor
|
Below are MeSH descriptors whose meaning is more general than "Vasoconstrictor Agents".
Below are MeSH descriptors whose meaning is more specific than "Vasoconstrictor Agents".
This graph shows the total number of publications written about "Vasoconstrictor Agents" by people in this website by year, and whether "Vasoconstrictor Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 1 | 1 | 2 |
| 1996 | 1 | 0 | 1 |
| 1997 | 0 | 1 | 1 |
| 1998 | 1 | 0 | 1 |
| 1999 | 2 | 1 | 3 |
| 2001 | 0 | 2 | 2 |
| 2003 | 0 | 1 | 1 |
| 2004 | 2 | 2 | 4 |
| 2005 | 4 | 2 | 6 |
| 2006 | 2 | 3 | 5 |
| 2007 | 1 | 2 | 3 |
| 2008 | 1 | 2 | 3 |
| 2009 | 0 | 2 | 2 |
| 2010 | 3 | 2 | 5 |
| 2011 | 1 | 1 | 2 |
| 2012 | 0 | 1 | 1 |
| 2013 | 1 | 0 | 1 |
| 2014 | 1 | 2 | 3 |
| 2015 | 3 | 0 | 3 |
| 2016 | 2 | 3 | 5 |
| 2017 | 2 | 1 | 3 |
| 2018 | 2 | 3 | 5 |
| 2019 | 4 | 4 | 8 |
| 2020 | 4 | 5 | 9 |
| 2021 | 1 | 3 | 4 |
| 2022 | 0 | 3 | 3 |
| 2023 | 0 | 5 | 5 |
| 2024 | 4 | 0 | 4 |
To return to the timeline,
click here.
Below are the most recent publications written about "Vasoconstrictor Agents" by people in Profiles.
-
The Association Between Vasopressin and Adverse Kidney Outcomes in Children and Young Adults Requiring Vasopressors on Continuous Renal Replacement Therapy. Crit Care Explor. 2024 Oct; 6(10):e1156.
-
Comparing risk of post infection erectile dysfunction following SARS Coronavirus 2 stratified by acute and long COVID, hospitalization status, and vasopressor administration: a U.S. large claims database analysis. Int J Impot Res. 2025 May; 37(5):366-371.
-
Controversies in terlipressin and transplantation in the United States: How do we MELD the two? Liver Transpl. 2024 Jul 01; 30(7):753-759.
-
From past to present to future: Terlipressin and hepatorenal syndrome-acute kidney injury. Hepatology. 2025 Jun 01; 81(6):1878-1897.
-
Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography. Hepatology. 2024 05 01; 79(5):1048-1064.
-
Decreased need for RRT in liver transplant recipients after pretransplant treatment of hepatorenal syndrome-type 1 with terlipressin. Liver Transpl. 2024 04 01; 30(4):347-355.
-
Management of Vasoplegic Shock in the Cardiovascular Intensive Care Unit after Cardiac Surgery. Crit Care Clin. 2024 Jan; 40(1):73-88.
-
The Effect of Terlipressin on Renal Replacement Therapy in Patients with Hepatorenal Syndrome. Kidney360. 2023 08 01; 4(8):1030-1038.
-
Terlipressin Treatment Is Associated With Reversal of Hepatorenal Syndrome in Patients With Alcoholic Hepatitis. Clin Gastroenterol Hepatol. 2023 12; 21(13):3455-3457.e3.
-
Terlipressin use and respiratory failure in patients with hepatorenal syndrome type 1 and severe acute-on-chronic liver failure. Aliment Pharmacol Ther. 2022 10; 56(8):1284-1293.